Prevent Blindness has launched its first-ever Geographic Atrophy (GA) Awareness Week from December 6-12, 2021. GA is an advanced form of dry age-related macular degeneration (commonly referred to as AMD) which leads to vision loss in the center of one’s vision. Geographic atrophy results in areas of damaged tissue causing central blind spots. It is [Read More]
Author: Dan Roberts
FDA Approves First Biosimilar Drug for Treatment of Wet AMD
The U.S. Food and Drug Administration (FDA) has approved Byooviz (ranibizumab-nuna) as the first biosimilar to Lucentis (ranibizumab injection) for the treatment of wet AMD. Byooviz is also approved to treat macular edema and myopic choroidal neovascularization, a vision-threatening complication of myopia (nearsightedness). The drug is administered by intravitreal injection (delivered into the vitreous humor [Read More]
FDA Approves Genentech’s Susvimo, a First-of-Its-Kind Therapeutic Approach for Wet Age-Related Macular Degeneration (AMD)
Susvimo, previously called Port Delivery System with ranibizumab, is the first wet AMD treatment in 15 years to provide an alternative to standard-of-care eye injections needed as often as once a month. By continuously delivering medicine into the eye through a refillable implant, Susvimo may help people with wet AMD maintain their vision with as [Read More]
Living Well With Low Vision: Miscellaneous Thoughts
by Dan Roberts Table of Contents About the Author I’m Visually Impaired, But . . . Twenty Things Eye Doctors Probably Don’t Tell You (But Would Like You To Know) Catching The Big One Correcting Misconceptions About AMD Detours Every Patient Can Be an Advocate Former Driver, Retired With Honor Hidden Disabilities: A Social Dilemma [Read More]
Port Delivery System Under Priority Review by FDA
Frequent Eye Injections May Soon Be History Genentech Pharmaceuticals has announced that the U.S. Food and Drug Administration (FDA) is giving priority review for the company’s Port Delivery System for the treatment of wet age-related macular degeneration (AMD). If approved, PDS will be a first-of-its-kind therapeutic approach, offering people living with wet AMD an alternative [Read More]